Enlivex Ltd.
IPOEnlivex | Quality Longevity & Prediction Markets Treasury
- Headquarters
- Ness Ziona
- Employees
- 11–50
- Founded
- 2005
- Business Model
- B2B
- Website
- enlivex.com
- Total Funding
- $220.0M
- Last Round
- $8.0M Series B
- Rounds
- 2
- Type
- Public
About
Enlivex is a Nasdaq-listed clinical-stage immunotherapy company developing Allocetra™, an off-the-shelf macrophage reprogramming cell therapy targeting inflammatory diseases including age-related knee osteoarthritis. Phase II data demonstrated 72% pain reduction and 109% functional improvement across over 250 patients, addressing a market valued at over $314 billion.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
World-leading Canadian cannabis company cultivating and selling medicinal and recreational cannab...
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...